Practical Guidance on the Clinical Management of Ocular Adverse Events Associated with Belantamab Mafodotin for...

Area of Science:

• Hematology
• Oncology
• Ophthalmology

Background:

• Multiple myeloma is a leading cause of cancer mortality globally.
• Latin America faces significant challenges in multiple myeloma outcomes due to access and equality barriers.
• Belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen, offers a novel therapeutic approach.

Purpose of the Study:

• To develop region-appropriate guidance for managing ocular adverse events associated with belantamab mafodotin in Latin America.
• To provide practical recommendations for healthcare professionals treating relapsed/refractory multiple myeloma patients.
• To foster multidisciplinary collaboration between hematologists/oncologists and ophthalmologists.

Main Methods:

• Convening a multidisciplinary panel of 13 experts in hematology/oncology and ophthalmology from Argentina, Brazil, Colombia, and Mexico.
• Reviewing evidence from recent phase 3 trials (DREAMM-7 and DREAMM-8).
• Developing practical recommendations through expert discussion and clinical trial experience.

Main Results:

• Belantamab mafodotin demonstrated notable efficacy in combination regimens for relapsed/refractory multiple myeloma.
• Ocular adverse events are anticipated with belantamab mafodotin, consistent with its mechanism of action.
• The expert panel established recommendations for identifying, managing, and collaborating on ocular events.

Conclusions:

• Clear, region-specific guidance is crucial for managing belantamab mafodotin-associated ocular adverse events.
• Multidisciplinary collaboration and patient-centric care are essential for optimal outcomes.
• These recommendations aim to support healthcare professionals across Latin America in optimizing treatment for multiple myeloma patients.